Doraiswamy P Murali, Varia Indira, Hellegers Caroline, Wagner H Ryan, Clary Greg L, Beyer John L, Newby L Kristin, O'Connor John F, Beebe Katherine L, O'Connor Christopher, Krishnan K Ranga
Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA.
Psychopharmacol Bull. 2006;39(1):15-24.
Noncardiac chest pain occurs frequently in medical practice and is often difficult to treat. We conducted a randomized double-blind, placebo-controlled, 8-week trial of paroxetine in 50 patients with noncardiac chest pain. None of the patients met criteria for panic disorder or major depression. Paroxetine-treated patients showed greater (P < .05) improvements than placebo-treated patients on the Clinical Global Impressions (CGI) scale. Both paroxetine and placebo-treated patients improved to a similar extent on selfrated pain measures, although baseline differences limited the interpretation of this outcome variable. There were no differences on other outcome ratings. Treatment was well tolerated. These preliminary findings extend other data on the potential of selective serotonin reuptake inhibitors for the acute treatment of noncardiac chest pain. Some recommendations for future studies to definitively test this potential are presented.
非心源性胸痛在医疗实践中很常见，且往往难以治疗。我们对50例非心源性胸痛患者进行了一项为期8周的随机双盲、安慰剂对照试验，使用帕罗西汀进行治疗。所有患者均不符合惊恐障碍或重度抑郁症的标准。在临床总体印象（CGI）量表上，帕罗西汀治疗组患者的改善程度大于安慰剂治疗组患者（P < .05）。尽管基线差异限制了对这一结果变量的解读，但帕罗西汀治疗组和安慰剂治疗组患者在自评疼痛指标上的改善程度相似。在其他结果评分方面没有差异。治疗耐受性良好。这些初步研究结果扩展了关于选择性5-羟色胺再摄取抑制剂治疗非心源性胸痛潜力的其他数据。本文还提出了一些未来研究的建议，以明确检验这一潜力。
